Back to discover
Drug

Gemfibrozil

In clinical development
ClassPeroxisome proliferator-activated receptor alpha agonistEmerging researchLate-stage developmentRising momentum
Also known as Gemcor, Lopid, Gemfibrozilo, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure+3 more

Gemcor, Lopid, Gemfibrozilo, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure, 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, Gemfibrozilum.

RxNorm4719ChEMBLCHEMBL457ATCC10AB04UNIIQ8X02027X3
3
Research papers
1
Active clinical trials
PPARA
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease

Clinical trial2025-10-15Results expected Q4 2028 · ClinicalTrials.gov

An Open-Label, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Itraconazole, Multiple Oral Doses of Gemfibrozil, and Single Oral Dose of Cyclosporine, on the Pharmacokinetics of a Single Oral Dose of RO7795081 in Healthy Participants

Clinical trial2025-06-16Completed · ClinicalTrials.gov

A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions

Clinical trial2025-03-26Results posted · ClinicalTrials.gov

A Phase 1, Open-label Study Evaluating the Effect of VX-993 on the Pharmacokinetics of Midazolam, and the Effect of Itraconazole and Gemfibrozil on the Pharmacokinetics of VX-993, in Healthy Adults

Clinical trial2024-07-02Completed · ClinicalTrials.gov

Neuroprotective effects of gemfibrozil in neurological disorders: Focus on inflammation and molecular mechanisms.

Research2023-10-30CNS neuroscience & therapeutics

A Phase 1, 3-arm, Open-label, Sequential Design Study to Investigate the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on Single-dose Pharmacokinetics of BMS-986278 in Healthy Participants

Clinical trial2023-10-23Completed · ClinicalTrials.gov

A Phase 1, Single-Center, Parallel-Group, Open-Label, Randomized, Drug-Drug Interaction Study to Assess the Effect of Itraconazole, Phenytoin, and Gemfibrozil on the Pharmacokinetics of a Single Oral Dose of BMS-986166 in Healthy Participants

Clinical trial2022-04-27Completed · ClinicalTrials.gov

A Three-part, Single-center, Open-label, Phase I Drug-drug Interaction Clinical Study to Investigate the Effect of Itraconazole, Gemfibrozil or Rifampicin on Pharmacokinetics of SKLB1028 in Healthy Subjects

Clinical trial2021-11-01Primary completion · ClinicalTrials.gov

A Phase 1, Single-center, Open-label, Two-cohort, Two-period, One-sequence, Two Treatment, Drug-drug Interaction Study of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Subjects

Clinical trial2020-07-08Completed · ClinicalTrials.gov

A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects

Clinical trial2019-08-28Completed · ClinicalTrials.gov

Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

Research2009-10-01Journal of acquired immune deficiency syndromes (1999)

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Research1999-08-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Gemfibrozil
Aliases & brands
GemcorLopidGemfibrozilo2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure2,2-Dimethyl-5-(2,5-xylyloxy)valeric acidGemfibrozilum
RxNorm CUI
4719
ChEMBL ID
CHEMBL457
ATC codes
C10AB04
UNII
Q8X02027X3
Primary mechanism
Peroxisome proliferator-activated receptor alpha agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Peroxisome proliferator-activated receptor alpha
PPARA · Q07869
AGONISTPeroxisome proliferator-activated receptor alpha agonist

Clinical trials

33 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
33
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
1
Recruiting
3
Late-stage (III+)
29
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 33
Early Phase 11Phase 124Phase 25Phase 31Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques: a Randomised Microarray-Study on Endarterectomy Specimens of Human Carotid Arteries

WithdrawnPH IVUniversity Hospital Muenstern=1002007

CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

CompletedPH IIIKey trialVA Office of Research and Developmentn=2,5311999

Recent completions

Trials that read out recently, adding to the completed evidence base.

An Open-Label, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Itraconazole, Multiple Oral Doses of Gemfibrozil, and Single Oral Dose of Cyclosporine, on the Pharmacokinetics of a Single Oral Dose of RO7795081 in Healthy Participants

CompletedPH IHoffmann-La Rochen=362025

A Phase 1, Open-label Study Evaluating the Effect of VX-993 on the Pharmacokinetics of Midazolam, and the Effect of Itraconazole and Gemfibrozil on the Pharmacokinetics of VX-993, in Healthy Adults

CompletedPH IVertex Pharmaceuticals Incorporatedn=422024

A Phase 1, 3-arm, Open-label, Sequential Design Study to Investigate the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on Single-dose Pharmacokinetics of BMS-986278 in Healthy Participants

CompletedPH IBristol-Myers Squibbn=472023

A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions

CompletedPH IBellus Health Inc. - a GSK companyn=452023

A Phase 1, Single-Center, Parallel-Group, Open-Label, Randomized, Drug-Drug Interaction Study to Assess the Effect of Itraconazole, Phenytoin, and Gemfibrozil on the Pharmacokinetics of a Single Oral Dose of BMS-986166 in Healthy Participants

CompletedPH IBristol-Myers Squibbn=152022

A Phase 1, Single-center, Open-label, Two-cohort, Two-period, One-sequence, Two Treatment, Drug-drug Interaction Study of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Subjects

CompletedPH ISanofin=302020

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19992024
Major research themes2
Neuroprotective Agents1Parkinson Disease1
Journals, researchers & institutions
Top journals
  • CNS neuroscience & therapeutics1
  • Journal of acquired immune deficiency syndromes (1999)1
  • The New England journal of medicine1
Leading researchers
  • Achmad H1
  • Alfaro RM1
  • Alsaab HO1
  • Alwaily ER1
  • Anderson JW1
  • Busse KH1
  • Chairez C1
  • Collins D1
Leading institutions
free-text, unnormalised
  • Center for Chronic Disease Outcomes Research1
  • Clinical Pharmacokinetics Research Laboratory1
  • College of Pharmacy1
  • Department of Medical Laboratory Sciences1
  • Hasanuddin University1
  • Institute of Pharmaceutical Research1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials